ClinicalTrials.gg
RecruitingNCT06802913Mela-NiaUpdated Jul 18, 2025

A Novel Inhaled Formulation of Melatonin to Treat Adults With Insomnia: Efficacy Study

An Early Phase 1 interventional study of Inhaled Melatonin (100 μg) and Oral Melatonin (4 mg) in Insomnia, sponsored by Woolcock Institute of Medical Research. Recruiting at 1 site in Australia. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Woolcock Institute of Medical Research · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders — 8 open to participants now, 8 under way, 2 of them phase 3. Melatonin · Sleep Initiation and Maintenance Disorders.

Planned enrollment
22nd of 25
10 · median 59
Started
2025
with 3 others
Phase 1
3 of 25
2 open now
Registered
19th of 25
by date
Lead sponsor
2 of 25
Woolcock Institute of Medical Research

Among the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, this one is the 22nd largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 1, and was the 19th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

8 of the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About melatonin

Melatonin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The goal of this clinical trial is to explore the potential benefits of an inhaled version of melatonin compared to oral melatonin tablets on adults with insomnia. The main question the trial aims to answer is: does inhaled melatonin affect the sleep profiles of adults with insomnia differently than oral melatonin tablets?

10 Participants will:

  • Visit the research institute for a screening visit, for an overnight visit at the beginning of each study drug treatment and for a blood collection visit at the end of the conclusion of each study drug treatment period (5 visits in total)
  • Take 100 µg of inhaled melatonin (2 inhaler puffs) nightly for two weeks
  • Take a 4 mg of oral melatonin (2 tablets) nightly for two weeks
Read the detailed description

This is a randomised open-label cross-over study of an inhaled formulation of melatonin (100 µg) versus oral melatonin tablets (4 mg) in adults with insomnia. The experiments performed for this trial will examine the effects of inhaled and oral melatonin on sleep microarchitecture such as sleep onset latency.

To be enrolled in the trial, participants are required to complete an online pre-screening survey. Eligible participants will be directed to a separate webpage where they will be invited to review and download the Participant Information Sheet (PIS) and asked to provide their contact details and consent for a follow up call/email from the research team to book in a screening visit. At the screening visit, the study team will explain the study to each participant and provide the opportunity to ask any questions. The study team will also ensure participants have had ample time prior to the visit to read and understand the PIS. The consent form will be signed by both the participant and a medical officer and participants. Once participants have joined the efficacy study, they will be randomised into their first treatment group; inhaled melatonin (100 µg) or oral melatonin tablets (4 mg).

Participants will attend the laboratory for an overnight visit then be treated with either inhaled melatonin or oral melatonin tablets before completing an overnight polysomnography sleep study. After the sleep study, participants will continue to take the study drug every night for two weeks and complete a sleep diary each morning to assess participant subjective perception of sleep quality. Once the two weeks of treatment have been completed, participants will visit the laboratory again to provide a blood sample that will be examined for biomarkers of neuroinflammation. There will be a 1 week washout period between treatment periods.

The study will recruit primarily through social media advertisements. The study will be coordinated from the Woolcock Institute of Medical Research, Sydney, Macquarie University, NSW, 2113, Australia.

03

Conditions studied

  • Insomnia

Keywords

  • Melatonin
  • Insomnia
  • Polysomnography
  • Biomarkers
  • Inhaled Therapy
  • Sleep Onset Latency
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of insomnia disorder as defined by the (difficulty initiating or maintaining sleep or waking up too early for at least 3 nights per week, for at least 3 months, with adequate opportunity and circumstances for sleep and at least one daytime impairment related to the sleep difficulty) and a score ≥15 on the ISI.
  • History of subjective sleep onset latency (sSOL) ≥30 minutes on at least 3 nights per week in the previous 4 weeks.
  • Able to provide informed electronic consent.
  • Fluent English literacy.
  • Adults aged 55+ years old.

Exclusion criteria

Exclusion Criteria:

  • People highly dependent on medical care as determined by a medical officer.
  • Untreated moderate-severe sleep apnoea as diagnosed using in-home wrist oximetry (oxygen desaturation index>15, ongoing effectively treated sleep apnoea with insomnia will be allowed).
  • Circadian disorders, narcolepsy, severe restless legs syndrome, and REM sleep behaviour disorder or uncontrolled psychiatric disorders.
  • History of attempted suicide or current suicide ideation (indicated by a score >0 on Q9 of the Patient Health Questionnaire-9) at pre-screening.
  • Objective cognitive decline measured by scoring ≤26 on the (MoCA)
  • Regular shift work, jet lag or trans-meridian travel (over 2h time difference) in the past week before randomisation.
  • Pregnancy or lactation. Female participants of with a fertile sexual partner must have a negative serum pregnancy test result at the screening visit. Women will be advised to use for the duration of the study.
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with clinical study procedures.
  • Currently participating in or has participated in a research study of an agent or device within 4 weeks of enrolment.
  • Ongoing use of anti-psychotic medication, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine or illicit stimulants.
  • Regular use of hypnotics (including melatonin, valerian, kava, benzodiazepines and Z-drugs), and other medications that can cause additive sedation (e.g. sedating antihistamines, tricyclic antidepressants, antipsychotics) within 14 days or 4-5 half-lives (whichever is longer) of starting the clinical trial.
  • Regular use of psychostimulants (e.g., dexamfetamine, lisdexamfetamine, methylphenidate) or non-amphetamine psychostimulants (e.g., armodafinil, modafinil, atomoxetine) within 14 days or 4-5 half-lives (whichever is longer) of starting the clinical trial.
  • Use of antidepressant medications for treatment of low mood for less than one year or dose changes (escalation or tapering) or change in antidepressant medications within the past year.
  • Regular use opioids within 14 days or 4-5 half-lives (whichever is longer) of starting the clinical trial.
  • Ongoing use of THC- or CBD-containing products within 14 days prior to the start of the trial.
  • Dependence or any other drug or alcohol dependence within the past two years (alcohol to be limited to no more than 2 standard drinks per day during trial period).
  • Regular use of drugs that are CYP1A2 inhibitors (e.g. amiodarone, cimetidine, ciprofloxacin, fluvoxamine) or CYP1A2 inducers (e.g. carbamazepine, phenobarbital, rifampin, tobacco).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Inhaled Melatonin Arm

    100 µg daily of inhaled melatonin delivered by pressurized metered dose inhaler for two weeks before habitual bedtime.

    Drug: Inhaled Melatonin (100 μg)

  • Active comparator
    Oral Melatonin Arm

    4 mg daily of orally delivered melatonin tablets for two weeks before habitual bedtime.

    Drug: Oral Melatonin (4 mg)

Interventions

  • An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.

    Also known as: Melatonin

  • Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.

    Also known as: N-Acetyl-5-methoxytryptamine, Circadin, Melatonin

06

What researchers measure

Primary outcomes

  1. Sleep onset latency

    Sleep onset latency (minutes) as assessed by polysomnography (PSG) on the first night of therapy. Sleep onset latency is the time between lights out and the first 30 second epoch scored as sleep using the American academy of sleep medicine criteria.

    Time frame: Day 1

Secondary outcomes

  1. Insomnia Severity Index

    The Insomnia Severity Index (ISI) is a 7-item questionnaire used to examine overall insomnia severity. It consists of a five-point Likert type scale for each item (ranging from "no problem" = 0 to "severe problem" = 28) regarding symptoms over the past 2 weeks. Scores range from 0-28 with higher scores indicating greater insomnia symptom severity.

    Time frame: Measured during the initial screening visit and day 14 of treatment.

  2. Wake after sleep onset

    Wake after sleep onset (WASO) is measured in minutes and is calculated from the first epoch of any sleep detected on the polysomnogram until the last epoch of sleep detected on the polysomnogram.

    Time frame: Day 1

  3. Total sleep time

    Total sleep time (TST) is measured in minutes and is the sum of all 30 second epochs scored as sleep during an overnight polysomnogram.

    Time frame: Day 1

  4. Participant perception of sleep quality

    Ordinal rating of sleep quality (How would you rate the quality of your sleep? 9 = best ever sleep, 5 = neither best nor worst sleep, 1 = worst sleep ever), assessed in the Karolinska sleep diary after waking every day for two weeks.

    Time frame: Every observation for two weeks

Other outcomes

  1. Traditional sleep staging

    Proportion of the sleep opportunity scored at the 5 stages (wake, and N1, N2, N3, and REM sleep) between lights out and lights on, measured using overnight in-laboratory polysomnography, scored by a polysomnography technician in accordance with AASM Sleep Scoring criteria.

    Time frame: Day 1

  2. Absolute Electroencephalography (EEG) Power During Non-Rapid Eye Movement (NREM) Sleep

    Spectral power of low delta (0.5-1 Hz), delta (1-4.5 Hz), theta (4.5-8 Hz), alpha (8-12 Hz), sigma (12-15 Hz), beta (15-25 Hz), and gamma (25-40 Hz) frequency ranges between treatment arms. Power spectral analysis will be applied to EEG signals from polysomnography during NREM sleep after artefacts are detected and removed.

    Time frame: Day 1

  3. Absolute Electroencephalography (EEG) Power During Rapid Eye Movement (REM) Sleep

    Spectral power of low delta (0.5-1 Hz), delta (1-4.5 Hz), theta (4.5-8 Hz), alpha (8-12 Hz), sigma (12-15 Hz), beta (15-25 Hz), and gamma (25-40 Hz) frequency ranges between treatment arms. Power spectral analysis will be applied to EEG signals from polysomnography during REM sleep after artefacts are detected and removed.

    Time frame: Day 1

  4. Blood levels of glial fibrillary acidic protein

    Blood-based glial fibrillary acidic protein (GFAP) within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  5. Blood levels of interleukin-6

    Blood-based interleukin-6 (IL-6), as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  6. Blood levels of plasma tau

    Blood-based plasma tau within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  7. Blood levels of granulocyte-macrophage colony-stimulating factor

    Blood-based granulocyte-macrophage colony-stimulating factor (GM-CSF) within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  8. Blood levels of brain derived neurotrophic factor

    Blood-based brain derived neurotrophic factor (BDNF) within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  9. Blood levels of neurofilament light chain

    Blood-based neurofilament light chain (NFL) within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  10. Blood levels of amyloid β (Aβ)

    Blood-based Aβ (Aβ40:Aβ42 ratio) within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

  11. Blood levels of C-reactive protein

    Blood-based C-reactive protein (CRP) within each participant, as measured by SIMOA blood neuro-metabolite assay.

    Time frame: Day 14 of treatment.

07

Study locations

1 of 1 sites recruiting
  • Woolcock Institute of Medical Research
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
    • Grigori Kaplan, PhD · Contactgrigori.kaplan@sydney.edu.au · +61 2 9805 3232
    • Hui Xin Ong, PhD · Principal investigator
    • Ron Grunstein, MBBS MD PhD FRACP · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.

Time frame: Non-identifiable IPD will become available one year after the Actual Study Completion Date and will remain available for fifteen years.

Access criteria: Following Macquarie University access terms, access restrictions will be limited to appropriate permission, project proposal and approved from the investigator team and data custodian. Any Recipients of the data must obtain project and HREC approval prior to mediated access. The Coordinating Principal Investigator, Dr. Hui Xin Ong, will be retain access the de-identified data, stored on the Macquarie University Research Data Repository (RDR).

Data sharing details ↗ · libguides.mq.edu.au

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 5 months after the start.

Of 39 phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 5 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2025
First posted
Jan 31, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 2025
CompletionEst.
May 2026
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06802913
Lead sponsor
Woolcock Institute of Medical Research
Responsible party
Hui Xin Ong (Dr, Woolcock Institute of Medical Research) — Principal investigator
First posted
Jan 31, 2025
Start date
Jul 1, 2025
Primary completion
Dec 2025 (estimated)
Completion
May 2026 (estimated)
Last update
Jul 18, 2025

Study contacts

Hui Xin Ong, PhD
Contact
huixin.ong@mq.edu.au
0298053094
Mathew N Leslie, PhD
Contact
mat.leslie@woolcock.org.au
0298053094
Hui Xin Ong, PhD
principal investigator · Woolcock Institute of Medical Research
Ron Grunstein, MBBS MD PhD FRACP
principal investigator · Woolcock Institute of Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion